Evidence map›Paper›PMID 42676331›Full record

ArticleLe Mali medical2025

[Renal Damage In Sickle Cell Disease: The Experience Of A Sickle Cell Reference Center In Sub-Saharan Africa].

Maxime Keita, Abdoul Karim Dembélé, Mariam Kanta, Ismael Kamara, Aldiouma Guindo, Saharé Fongoro, Kaya Assétou Souckho, Aissata Diebkilé Tolo, Dapa Aly Diallo

Abstract readEnglish Abstract
In one paragraph

Article in Le Mali medical, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maxime KeitaCentre de recherche et de lutte contre la drépanocytose (CRLD).
Abdoul Karim DembéléCentre de recherche et de lutte contre la drépanocytose (CRLD).
Mariam KantaCentre de recherche et de lutte contre la drépanocytose (CRLD).
Ismael KamaraService d'hématologie clinique du CHU du Point G, Bamako (Mali).
Aldiouma GuindoCentre de recherche et de lutte contre la drépanocytose (CRLD).
Saharé FongoroService de néphrologie du CHU du Point G, Bamako (Mali).
Kaya Assétou SouckhoService de médecine interne du CHU Point G, Bamako (Mali).
Aissata Diebkilé ToloService d'hématologie clinique du CHU de Yopougon, Abidjan (Côte d'Ivoire).
Dapa Aly DialloCentre de recherche et de lutte contre la drépanocytose (CRLD).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: renal damage, often due to impaired glomerular function, is a progressive complication associated with high mortality in sickle cell disease. Few studies report on this complication in the context of organized care in sub-Saharan Africa. Objective: to describe renal damage in sickle-cell patients attending in sickle-cell referral center in sub-Saharan Africa. Patients and Methods: a descriptive and analytical study with retrospective data collection was carried out from March 2010 to March 2017, at the «Centre de Recherche et de Lutte contre la Drépanocytose» of Bamako, Mali. Results: 125 sickle cell disease patients, including 70 SS, 43 SC, 10 Sβ+thalassemics and 2 Sβ°thalassemics, distributed between 67 women and 58 men with a mean age of 33.03 ± 15.53 years, were identified. Renal damage was documented by sickle cell nephropathy (84.8%), CKD (10.4%) and hematuria (4.8%); it was significantly associated with a history of hypertension, diabetes or non-steroidal antiinflammatory drugs use (p < 0.05), but was not observed in patients with fœtal hemoglobin > 20%. Five patients (4%) were on chronic kidney dialysis. Conclusion: the precocity and high frequency of renal damage in sickle-cell patients in sub-Saharan Africa call for studies to identify the risk factors for this complication in a cohort of sickle-cell patients followed up from birth.

Indexed as

Anemia, Sickle CellKidney DiseasesRenal Insufficiency, ChronicAdolescentAdultAfrica South of the SaharaFemaleHematuriaHumansHypertensionMaleMaliMiddle AgedRetrospective StudiesRisk FactorsYoung Adultkidneynon-steroidal antiinflammatory drugsreference centersickle cell diseasesub-Saharan Africa

Identifiers

PMID42676331
PMCPMC13103454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.